These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 1982264

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype.
    Colado MI, Williams JL, Green AR.
    Br J Pharmacol; 1995 Aug; 115(7):1281-9. PubMed ID: 7582557
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Methylenedioxymethamphetamine: a potentially neurotoxic amphetamine analogue.
    Schmidt CJ, Wu L, Lovenberg W.
    Eur J Pharmacol; 1986 May 13; 124(1-2):175-8. PubMed ID: 2424776
    [Abstract] [Full Text] [Related]

  • 25. Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats.
    Stone DM, Hanson GR, Gibb JW.
    Neuropharmacology; 1987 Nov 13; 26(11):1657-61. PubMed ID: 2448703
    [Abstract] [Full Text] [Related]

  • 26. The neurochemical and stimulatory effects of putative metabolites of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine in rats.
    Yeh SY, Hsu FL.
    Pharmacol Biochem Behav; 1991 Jul 13; 39(3):787-90. PubMed ID: 1723801
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Effect of repeated ('binge') dosing of MDMA to rats housed at normal and high temperature on neurotoxic damage to cerebral 5-HT and dopamine neurones.
    Sanchez V, O'shea E, Saadat KS, Elliott JM, Colado MI, Green AR.
    J Psychopharmacol; 2004 Sep 13; 18(3):412-6. PubMed ID: 15358986
    [Abstract] [Full Text] [Related]

  • 29. Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices.
    Fitzgerald JL, Reid JJ.
    Eur J Pharmacol; 1990 Nov 27; 191(2):217-20. PubMed ID: 1982265
    [Abstract] [Full Text] [Related]

  • 30. Reversal of the acute effects of 3,4-methylenedioxymethamphetamine by 5-HT uptake inhibitors.
    Schmidt CJ, Taylor VL.
    Eur J Pharmacol; 1990 May 31; 181(1-2):133-6. PubMed ID: 1974853
    [Abstract] [Full Text] [Related]

  • 31. Inhibition of dopamine release by methylenedioxymethamphetamine is mediated by serotonin.
    Gazzara RA, Takeda H, Cho AK, Howard SG.
    Eur J Pharmacol; 1989 Sep 13; 168(2):209-17. PubMed ID: 2575036
    [Abstract] [Full Text] [Related]

  • 32. The N-methyl-D-aspartate antagonist MK-801 protects against serotonin depletions induced by methamphetamine, 3,4-methylenedioxymethamphetamine and p-chloroamphetamine.
    Farfel GM, Vosmer GL, Seiden LS.
    Brain Res; 1992 Nov 06; 595(1):121-7. PubMed ID: 1361410
    [Abstract] [Full Text] [Related]

  • 33. The interactions of MK-801 with the amphetamine analogues D-methamphetamine (D-METH), 3,4-methylenedioxymethamphetamine (D-MDMA) or D-fenfluramine (D-FEN): neural damage and neural protection.
    Miller DB, O'Callaghan JP.
    Ann N Y Acad Sci; 1993 May 28; 679():321-4. PubMed ID: 8099774
    [No Abstract] [Full Text] [Related]

  • 34. MDMA: further evidence that its action in the medial prefrontal cortex is mediated by the serotonergic system.
    Pan HS, Wang RY.
    Brain Res; 1991 Jan 25; 539(2):332-6. PubMed ID: 1675911
    [Abstract] [Full Text] [Related]

  • 35. Evidence that both intragastric and subcutaneous administration of methylenedioxymethylamphetamine (MDMA) produce serotonin neurotoxicity in rhesus monkeys.
    Kleven MS, Woolverton WL, Seiden LS.
    Brain Res; 1989 May 29; 488(1-2):121-5. PubMed ID: 2472850
    [Abstract] [Full Text] [Related]

  • 36. Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain.
    Steele TD, Nichols DE, Yim GK.
    Biochem Pharmacol; 1987 Jul 15; 36(14):2297-303. PubMed ID: 2886126
    [Abstract] [Full Text] [Related]

  • 37. Alterations in hippocampal function following repeated exposure to the amphetamine derivative methylenedioxymethamphetamine ("Ecstasy").
    Sharkey J, McBean DE, Kelly PA.
    Psychopharmacology (Berl); 1991 Jul 15; 105(1):113-8. PubMed ID: 1684057
    [Abstract] [Full Text] [Related]

  • 38. Effects of ritanserin on the 3,4-methylenedioxymethamphetamine-induced decrease in striatal serotonin concentration and on the increase in striatal neurotensin and dynorphin A concentrations.
    Johnson M, Bush LG, Hanson GR, Gibb JW.
    Biochem Pharmacol; 1993 Aug 17; 46(4):770-2. PubMed ID: 8103327
    [Abstract] [Full Text] [Related]

  • 39. Neuroanatomic specificity and time course of alterations in rat brain serotonergic pathways induced by MDMA (3,4-methylenedioxymethamphetamine): assessment using quantitative autoradiography.
    Battaglia G, Sharkey J, Kuhar MJ, de Souza EB.
    Synapse; 1991 Aug 17; 8(4):249-60. PubMed ID: 1681594
    [Abstract] [Full Text] [Related]

  • 40. Serotonin neurotoxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans.
    McCann UD, Ridenour A, Shaham Y, Ricaurte GA.
    Neuropsychopharmacology; 1994 Apr 17; 10(2):129-38. PubMed ID: 7517677
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.